Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherap...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2023-01-01
|
Series: | Tuberculosis and Respiratory Diseases |
Subjects: | |
Online Access: | http://e-trd.org/upload/pdf/trd-2022-0081.pdf |